Trial Profile
An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRIGHT 1012
- Sponsors Pfizer
- 01 Aug 2022 Results published in the Annals of Hematology
- 14 Mar 2022 Status changed from active, no longer recruiting to completed.
- 24 Jan 2022 Planned End Date changed from 21 Dec 2021 to 6 Feb 2022.